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Abstract: The translationally controlled tumor protein (TCTP) plays a role in cell growth, cell cycle and cancer
progression. TCTP controls negatively the stability of the p53 tumor suppressor protein and interacts with the
cellular cytoskeleton. The deregulation of the actin and cytokeratin cytoskeleton is responsible for the increased
migratory activity of tumor cells and is linked with poor patient outcome. Recent studies indicate that cyclin A,
a key regulator of cell cycle, controls actin organization and negatively regulates cell motility via regulation of RhoA
expression. We studied the organization of actin and cytokeratin cytoskeleton and the expression of TCTP, p53,
cyclin A, RhoA and actin in HIO180 non-transformed ovarian epithelial cells, and OVCAR3 and SKOV3 (ex-
pressing low level of inducible p53) ovarian epithelial cancer cells with different metastatic potential. Immun-
ostaining and ultrastructural analyses illustrated a dramatic difference in the organization of the cytokeratin and actin
filaments in non-transformed versus cancer cell lines. We also determined that there is an inverse relationship be-
tween the level of TCTP/RhoA and actin/p53/cyclin A expression in ovarian cancer cell lines. This previously uniden-
tified negative relationship between TCTP/RhoA and actin/p53/cyclin A may suggest that this interaction is linked
with the high aggressiveness of ovarian cancers. (Folia Histochemica et Cytobiologica 2012, Vol. 50, No. 3, 358–367)
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Introduction
Translationally controlled tumor protein (TCTP) is
a multifunctional protein that is present and con-
served in all eukaryotic cells. It regulates cell growth,
cell cycle, apoptosis, malignant transformation and
cancer progression [1–6]. The silencing of TCTP in
tumor cells either reverts the malignant phenotype
or induces apoptosis [7–9], and the high expression
of TCTP and its function in the degradation of the
tumor suppressor protein p53 [10–14] correlates with
poorly differentiated and highly aggressive tumors
[15, 16]. Some of the regulatory functions of TCTP
in cell division, cell cycle progression, cell shape and
motility are likely related to its ability to bind to the
cellular cytoskeleton [17, 18]. The cellular cytoskel-
eton plays a role in cell architecture, function, and
oncogenic transformation. Numerous studies have
determined that, in various human cancers includ-
ing ovarian epithelial cancer, changes in the archi-
tecture and composition of the cytoskeleton are re-
sponsible for increased cancer cell invasiveness and
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metastasis and are linked with poor patient outcomes
[19–33]. Indeed, the pattern of cytokeratin expres-
sion is used as a diagnostic tool in tumor prognosis
[22, 25, 26]. Metastasis can occur via the reorgani-
zation of the cytokeratin and actin network archi-
tecture by altering the visco-elastic property of the
cells and facilitating their ability to change shape and
migrate through basement membranes and neigh-
boring tissues [20, 24]. The changes in actin organi-
zation, its expression level and its interaction with
binding partners are all responsible for the increased
migratory activity observed in various cancers, in-
cluding ovarian cancer [20, 21, 24, 27–29, 31–33],
which is one of the most lethal malignancies and the
fifth leading cause of cancer-related deaths in wom-
en in the United States [34, 35].
Because TCTP, and possibly p53, interact with
the cytoskeleton [17, 18, 36], the organization of
which is regulated by cyclin A via RhoA pathway
[37], and there is a negative feedback loop between
TCTP and p53 expression and function [15, 16], we
studied the organization of the cytokeratin and ac-
tin cytoskeleton and its relationship to TCTP, p53,
cyclin A and RhoA in non-transformed epithelial
ovarian HIO180 cells, and the epithelial ovarian can-
cer cell lines OVCAR3 and SKOV3. These two can-
cer cell lines possess different metastatic potential
[27, 38] and SKOV3 cells express a low level of in-
ducible p53 [39].
We established that TCTP is localized on actin fil-
aments and that there is an inverse relationship be-
tween TCTP/RhoA and p53/cyclin A/actin expression
in ovarian cancer cells, suggesting a negative feed-
back signaling between these molecules that may have
relevance to the high malignancy of ovarian tumors.
Material and methods
Cell lines and antibodies. The human ovarian surface epi-
thelial cell line HIO180 and two ovarian carcinoma cell lines,
OVCAR3 and SKOV3, were cultured in RPMI medium
supplemented with 10% FCS. For light and electron mi-
croscopy, cells for immunostaining were seeded on micro-
scope chamber slides. The following primary antibodies were
used in this study: FITC-conjugated and unconjugated anti-
pan cytokeratin clone C-11 mouse monoclonal antibody
(Sigma–Aldrich, St. Louis, MO, USA), anti-p53 rabbit poly-
clonal (Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA) or mouse monoclonal (Millipore, Billerica, MA,
USA) antibodies, anti-TCTP and anti-GAPDH rabbit poly-
clonal antibodies (Abcam, Cambridge, MA, USA), anti-cy-
clin A monoclonal and anti-RhoA polyclonal antibodies
(Santa Cruz Biotechnology) and anti-beta actin rabbit poly-
clonal antibody (Pierce, Thermo Fisher Scientific Inc., Rock-
ford, IL, USA).
Light microscopy. Cytokeratin immunostaining. Cells grown
on chamber slides were fixed in 1% formalin dissolved in
100% methanol overnight at –20°C. After rehydration and
washing with 1 × PBS + 0.05% Tween 20 (PBS-Tween),
cells were permeabilized with 0.1% Triton X-100 and washed
again in PBS-Tween; non-specific binding was blocked in
casein blocking buffer in PBS (Bio-Rad) for 1 hour. After
blocking, the cells were stained with a 1:400 dilution of FITC
conjugated anti-pan cytokeratin antibody for 1 hour. After
washing, the cells were mounted using antifade reagent
(Molecular Probes, Life Technologies, Grand Island, NY,
USA) containing propidium iodide (nucleic acid stain) and
photographed using a Nikon fluorescence microscope.
Actin staining. Cells grown on chamber slides were fixed in
4% formaldehyde (EM grade) in PBS with 0.1% Triton X-100
for 30 min at room temperature. After two 15 min washes in
PBS-Tween, the slides were blocked for 30 min using casein
blocking buffer (Bio-Rad) with 0.05% Tween in PBS and then
stained for 1 hr in rhodamine-phalloidin (5 μl of methanolic
stock solution of  200 U/ml per 200 μl of PBS + 1% BSA)
(Molecular Probes, Eugene, OR, USA). After washing in PBS +
+ Tween in the dark, the slides were mounted using an anti-
fade reagent containing DAPI (nuclear staining) and photo-
graphed using a Nikon fluorescence microscope.
Electron microscopy pre-embedding immunostaining. Cells
grown on chamber slides were fixed, as described above,
for either cytokeratin or actin. After blocking in casein block-
ing buffer (Bio-Rad), the cells were incubated in a 1:400 dilu-
tion of anti-pan cytokeratin antibody, a 1:50 dilution of an anti-
actin antibody or an anti-TCTP antibody. After washing, the
slides were incubated in a 1:50 dilution of nanogold-conjugated
secondary antibody, as described by Bilinski et al. [40]. After
extensive washing, cells were silver- or gold-enhanced using the
silver or gold enhancement kit, respectively, according to the
manufacturer’s protocol. The slides were then washed in mo-
lecular grade water and post-fixed in 2% glutaraldehyde in PBS.
After dehydration in a series of ethanol solutions, the cells were
embedded in Epon and sectioned for electron microscopy, as
described in Bilinski et al. [40]. In contrast to the standard elec-
tron microscopy fixation protocol, in immune-electron micros-
copy there is no post-fixation with osmium tetroxide, which in-
terferes with the nanogold-silver enhanced signal. Because os-
mium is not used in this procedure, the tissue contrast is much
lower than in standard electron microscopy images [40].
Western blotting. Cells were homogenized on ice in RIPA
buffer (0.15 M NaCl, 1% deoxycholate sodium salt, 1% Tri-
ton X-100, 0.1% SDS and 0.01 M Tris-HCl (pH 7.2)) in the
presence of a complete protease inhibitor (Roche, India-
napolis, IN, USA). The protein concentration was deter-
mined using Bio-Rad protein assay reagents. Proteins were
separated using pre-set 4–15% SDS-PAGE gels (Bio-Rad
Life Science, Hercules, CA, USA) and blotted to nitrocel-
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lulose membranes (Bio-Rad) using semi-dry blotting system
(Bio-Rad). Membranes were blocked in 5% milk (Bio-Rad)
for 1hour at room temperature and incubated with primary
antibodies against beta actin (1:1,000 dilution), TCTP (1:500
dilution), GAPDH (1:1,000 dilution), cyclin A (1:500 dilu-
tion), RhoA (1:500 dilution) and p53 (1:500 dilution) over-
night at 4°C. After washing, blots were incubated for 30 min
at room temperature in a 1:2,000 dilution of HRP-conjugat-
ed goat anti-mouse or goat anti-rabbit secondary antibodies
(Santa Cruz Biotechnology) and developed using the Lumi-
Light Western blotting kit (Roche) that contains the chemi-
luminescent HR substrate, and exposed to X-ray film (Phenix
Research Products, Candler, NC, USA). Band intensity was
quantified using the Quantity One 4.6.1 system (Bio-Rad).
Experiments were performed on triplicates of cell cultures.
The standard deviation values were calculated using an Ex-
cel program (Microsoft Corp., Redmond, WA, USA).
Results
Actin and cytokeratin architecture
With light microscopy and rhodamine-phalloidin
staining of actin, we observed striking differences
between the actin organization patterns across the
different cell lines (Figure 1). The HIO180 non-trans-
formed ovarian epithelial cell line displayed an abun-
dance of thin actin filaments criss-crossing through-
out the cytoplasm (Figure 1A). The OVCAR3 ovari-
an carcinoma cell line possessed thick actin filament
stress fibers that circumnavigated the cell periphery
(Figure 1B). In contrast, the SKOV3 ovarian carci-
noma cell line, which is more metastatic than the
OVCAR3 cells [27, 37], contained a few long actin
filaments that were concentrated at the cell periph-
ery, but the majority of the actin formed very short
filaments and comets (Figure 1C). An ultrastructural
analysis using immunogold labeling of actin confirmed
these dramatic differences in the organization and
distribution of actin among the different cell lines
(Figure 2). In the HIO180 cells, the silver-enhanced
nanogold label was localized to the thin actin filaments
(Figures 2A, A1). In the OVCAR3 cells, the label was
localized to the thick stress fibers (Figures 2B, B1),
and in the SKOV3 cells, the label was distributed on
the comets or short actin filaments within the cell body
(Figure 2C). It should be emphasized that, in con-
trast to the standard electron microscopy fixation pro-
tocol, for immune-electron microscopy there is no
post-fixation with osmium tetroxide; therefore, the
Figure 1. Actin and cytokeratin distribution across the ovarian cell lines. The HIO180 ovarian surface epithelial cell line
(A, A1) and two ovarian carcinoma cell lines, OVCAR3 (B, B1) and Skov3 (C, C1), were grown on chamber slides and
stained for actin using rhodamine-phalloidin (red). Nuclei (blue) were stained with DAPI. Panels A1–C1 contain the merged
images of actin and DAPI staining. (A–C): the bar is equal to 3 μm. HIO180 (D), OVCAR3 (E) and SKOV3 (F) cell lines
were grown on chamber slides and immunostained for cytokeratin with FITC-conjugated anti-pan cytokeratin antibody
(green). Nucleic acids (RNA and DNA) were stained with propidium iodide (red). (D–F): the bar is equal to 5 μm
A B C
E F
A1 B1 C1
HIO180 OVCAR3 SKOV3
HIO180 OVCAR3 SKOV3D
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Light microscopy visualization of immunostained
cytokeratin displayed prominent differences in cytok-
eratin distribution across the different cell lines (Fig-
ure 1). In the HIO180 cells, the cytokeratin filaments
were concentrated in the vicinity of the cell nucleus
and in the cytoplasm (Figure 1D). In the OVCAR3
cells, the cytokeratin formed an intricate basket-like
network of filaments encapsulating the nuclei and ex-
tending throughout the entire cytoplasm (Figure 1E).
In the SKOV3 cells, bundles of cytokeratin filaments
were concentrated at the cell periphery (Figure 1F).
TCTP is localized on actin but not on
cytokeratin filaments
To establish the relationship between TCTP and the
actin cytoskeleton, we performed double staining of
actin and TCTP. The HIO180, OVCAR3 and SKOV3
cells were stained with rhodamine-phalloidin for ac-
tin and immunostained with an anti-TCTP antibody
(Figure 3). In all cell types, TCTP was present in the
cell nucleus (Figures 3A–C1). In addition, in the
HIO180 cells, TCTP displayed a granular localiza-
tion pattern in the vicinity of and around the nucleus.
TCTP also localized to the actin filaments in these
cells (Figures 3A, A1). In the OVCAR3 cells, TCTP
also formed a granular pattern in the vicinity of the
nucleus and was clearly localized on the actin fila-
ments, stress fibers, and in the focal adhesions at the
cell periphery (Figures 3B, B1). In the SKOV3 cells,
some TCTP was located in the vicinity of the nucle-
us; however, most TCTP was localized at the cell pe-
riphery and in the focal adhesions (Figures 3C, C1).
We also performed ultrastructural analysis of
TCTP distribution on actin filaments. Cells were fixed
in an actin-preserving fixative (see Material and meth-
ods), and TCTP was visualized using a nanogold-con-
jugated secondary antibody and silver enhancement
(Figure 4). Ultrastructural analysis very clearly dis-
played that TCTP is localized on long actin filaments
in both the HIO180 (Figures 4A, B) and OVCAR3
(Figure 4D) cells. In the SKOV3 cells, in which the
majority of actin is organized in the form of comets
or very short filaments, the distribution of TCTP par-
alleled the distribution of actin and had both a spotty
and short filament type of localization (Figure 4E).
To establish the relationship between TCTP and
cytokeratin filaments, we fixed the cells in a cytoker-
atin filament-preserving fixative (see Material and
methods) and used nanogold immunostaining elec-
tron microscopy. This analysis determined that, in all
studied cell types, TCTP was localized in the vicinity
of the cytokeratin filaments, but not directly on the
filaments (Figure 5).
Figure 2. Electron microscopy of nanogold-immunostained
actin across the ovarian cell lines. HIO180 (A, A1), OVCAR3
(B, B1) and SKOV3 (C) cells grown on chamber slides were
fixed and then incubated with an anti-actin antibody followed
by a nanogold-conjugated secondary antibody. This was then
silver-enhanced, processed for EM and visible as nanogold
label (black dots) in the cytoplasm and cell nucleus (N)
A
B
C
A1
B1
HIO180
OVCAR3
SKOV3
500 nm 500 nm
2 microns 500 nm
2 microns
tissue contrast in these images is much lower than in
standard electron microscopy images [see Material
and methods and 40].
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Conversion between actin, p53, cyclin A
and TCTP/RhoA expression in different cell lines
Using the Western blot technique, we compared the
expression levels of TCTP, cyclin A, p53, RhoA and
actin across the different cell lines. The level of actin
was lower in the OVCAR3 and SKOV3 cancer cells
(36% and 38%, respectively) than in the HIO180 non-
transformed ovarian cells (Figure 6). Additionally, the
level of p53 protein and cyclin A expression had the
same trend and was dramatically lower in the
OVCAR3 and SKOV3 cells (60% and 47%, and 19%
and 11% of the control level respectively) than in the
HIO180 cells (Figure 6). Interestingly, while two dif-
ferent molecular weight isoforms of cyclin A were
present in non transformed HIO180 cells, a highly
abundant full length version and a low abundance
truncated version, only a low level of truncated cyclin A
isoform (cyclin At) was present in OVCAR3 and
SKOV3 cancer cell lines (Figure 6F). The level of
TCTP expression was approximately 30% higher in
the OVCAR3 cells than in the HIO180 or SKOV3
cells (Figure 6). The level of RhoA expression was
also higher in cancer cells than in HIO180 cells: about
42% higher in SKOV3 and 92% higher in OVCAR3
cells (Figure 6). Thus, Western blot analysis demon-
A
B
C
HIO180
OVCAR3
SKOV3
B1
C1
A1
Figure 3. Actin and TCTP co-localization across the ovarian cell lines. HIO180 (A, A1), OVCAR3 (B, B1) and SKOV3
(C, C1) cells were grown on chamber slides, stained for actin using rhodamine-phalloidin (A–C; red) and immunostained
with an anti-TCTP primary antibody and a FITC-conjugated secondary antibody (A1–C1; green). Nuclei (blue) were
stained using DAPI. Short arrows point at TCTP presence in the granules in the vicinity of the nucleus, and long arrows
— in focal adhesions. Panels A–C contain the merged images of actin and DAPI staining. The bar is equal to 10 μm
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Figure 4. Ultrastructural analysis of TCTP localization on actin filaments. The HIO180 (A–C), OVCAR3 (D) and SKOV3
(E) cells were grown on slides, fixed in actin filament-preserving fixative, incubated with an anti-TCTP antibody, followed
by a nanogold-conjugated secondary antibody, silver enhanced and processed for EM as described in methods. The silver-
enhanced, nanogold-labeled TCTP (black dots) exhibits an orderly localization pattern (arrows) along the long actin
filaments in both the HIO18 (A, B) and OVCAR3 (D) cell lines. In the SKOV3 cells, the TCTP label follows the granular
and short filaments pattern of actin distribution, with occasional longer filaments visible (E, arrow). Panel C depicts the
lack of labeling in the control sample, which did not contain an anti-TCTP primary antibody. The arrow points to the
unlabeled actin filaments. Mitochondria (m). Nucleus (N)
HIO180 TCTP HIO180 TCTP
HIO180 control OVCAR3 TCTP
SCOV3 TCTP
A B
C D
E
500 nm 500 nm
500 nm 500 nm
10 microns
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strated a strong positive relationship between the ex-
pression level of p53, cyclin A and actin and a nega-
tive relationship between the expression level of
TCTP/RhoA and p53/cyclin A/actin in all cell lines
tested (Figure 6).
Discussion
Our study established that there are differences in
the organization of the actin and cytokeratin cytosk-
eleton between normal epithelial ovarian cells and
ovarian cancer cell lines. Studies on various cancer
cells indicate that changes in the architecture and
composition of the cytoskeleton are responsible for
oncogenic transformation and increased cell motility
and invasiveness [19–33, 41, 42].
We found that SKOV3 cells displayed the most
dramatic changes in morphology, ultrastructure and
distribution of the actin cytoskeleton compared to the
less metastatic OVCAR3 cells or the non-transformed
HIO180 cells. It is possible that these changes are
responsible for the higher metastatic potential of
SKOV3 cells. We also observed that both cancer cell
lines tested had approximately 40% lower actin ex-
pression levels versus the non-transformed HIO180
cells. These observed differences in the organization
of the actin cytoskeleton and the concentration of
actin were previously described for MOSE cells, which
are a mouse model of progressive ovarian cancer.
Creekmore et al. [21] determined that, during the
malignant progression of MOSE-E (early) to MOSE-L
(late) cells, the long and well-defined cable-like actin
stress fibers are replaced by very short and thin actin
filaments and that these changes correlated with
a 78% reduction in actin concentration in the MOSE-L
cells. Another study illustrated that MOSE-E cells
are more rigid and viscous than MOSE-L cells [24].
These authors suggested that the reduction in actin
levels and the changes in the organization of the ac-
tin cytoskeleton are responsible for the changes in
the mechanical properties of cells and that the in-
creased cell deformability directly correlates with the
progression from a noncancerous to a malignant phe-
notype [21, 24]. Similar results were also reported
for several human ovarian cancer cell lines (ES-2a,
TOV-21Gb, RMG-Ic, OVMANAd, OVISEd, OVASd,
OVTOKOd, OVSAYOd, KKd, SMOV-2d, TOV-81D
and TOC-112D), where microarray and proteomic
analyses determined changes in the expression of cy-
toskeletal genes and proteins during the progression
from low- to high-grade ovarian cancer [43, 44].
We also found that the level of tumor suppressor
p53 protein expression is much lower in the OVCAR3
and SKOV3 cancer cell lines than in the non-cancer-
ous HIO180 cells. Importantly, the observed decrease
in p53 expression correlates with a reduction in actin
expression in these cells. The p53 protein has multi-
ple biological functions, including modulation of cell
growth and death. Additionally, mutations in the TP53
gene may lead to aberrant cell proliferation and on-
cogenic transformation [10, 11, 13]. Recent studies
have indicated that the activation of the p53 pathway
induces actin expression in normal macrophages, en-
dothelial cells, primary AML blasts and myeloid leu-
kemia cell lines, and that these changes are accom-
panied by changes in cell shape and morphology [36].
Figure 5. Ultrastructural analysis of cytokeratin and
localization of TCTP in relation to cytokeratin filaments
across the ovarian cell lines. Cells grown on slides were
fixed to preserve the cytokeratin filaments (see Material
and methods). The slides were incubated with either an
anti-pan cytokeratin (A) or anti-TCTP antibody (B, D, F),
followed by a nanogold-conjugated secondary antibody,
silver enhanced and processed for electron microscopy.
(A) HIO180 cells. Anti-cytokeratin immunostaining
illustrates a network of labeled cytokeratin filaments
(arrows) in the cytoplasm. (B) HIO180 cells, (D) OVCAR3,
(F) SKOV3 cells: TCTP is localized in the vicinity of, but not
on, the cytokeratin filaments (arrows). Control OVCAR3
(C) and SKOV3 (E) cells were incubated without anti-TCTP
primary antibody to demonstrate the unlabeled cytoplasm
and cytokeratin filaments (arrows). Nucleus (N)
500 nm
2 microns 500 nm
500 nm
500 nm 500 nm
A B
C D
E F
HIO180 CYTOKERATIN HIO180 TCTP
OVCAR3 control OVCAR3 TCTP
SCOV3 control SCOV3 TCTP
365TCTP in ovarian cancer cell lines
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2012
10.5603/FHC.2012.0049
www.fhc.viamedica.pl
HIO180 SKOV3 OVCAR3
150
100
50
0
TCTP
GAPDH
RHOA-GAPDH
GAPDH
RHOA
HIO180 SKOV3 OVCAR3
150
100
50
0
p53-GAPDH
HIO180 SKOV3 OVCAR3
p53
GAPDH
HIO180 SKOV3 OVCAR3
ACTIN
GAPDH
ACTIN-GAPDH
150
100
50
0
150
100
50
0
CYCLIN A-GAPDH
HIO180 SKOV3 OVCAR3
CYCLIN
GAPDH
A B
C D
E
GAPDH
p53
BA
TCTP
HIO180 SKOV3 OVCAR3
F
RHOA
CYC A
CYC A t
TCTP -GAPDH
150
100
50
0
Figure 6. Western blot analysis of TCTP, RhoA, p53, beta actin, and cyclin A compared to GAPDH protein expression across
the different cell lines. (A, B, F) TCTP and RhoA expression, (C, D, F) P53 and beta actin expression and (E, F) total cyclin A
(A plus At) expression in the SKOV3 and OVCAR3 ovarian epithelial cancer cell lines compared to the non-transformed
HIO180 cell line. In all graphs, the Y axes represent gel band pixel density (adjusted volume) presented in arbitrary units.
The standard deviation was calculated in Excel. Experiments were performed on three separate batches of cell cultures
Interestingly, we observed a negative relationship
between the level of p53/actin and TCTP protein ex-
pression in ovarian cancer cells. The existence of
a negative feedback loop between TCTP and p53 has
been recently reported by both Amson et al. [15] and
Rho et al. [16]. Amson et al. determined that TCTP
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regulates p53 by promoting its MDM2-mediated ubiq-
uitination and degradation, and that p53 binds to
a p53 responsive element in the TCTP promoter, lead-
ing to the transcriptional repression of TCTP [15].
Rho et al. established that the overexpression of
TCTP promoted the degradation of p53 and reversed
p53-mediated apoptosis, while an inhibition of TCTP
expression increased apoptosis in lung carcinoma cells
[16]. These findings indicate that there is a direct
molecular link between TCTP, which is a regulator of
tumor reversion, and tumor suppressor p53. Amson
et al. [15] suggested that, in some cancer types, the
specific mutation found in p53 results in high TCTP
activity that might contribute to oncogenesis. They
also demonstrated that, in cancer tumors with wild-
type p53, their high-TCTP status allows tumors to
promote the degradation of p53 and therefore abol-
ishes its tumor suppressor function.
Taken together with our data, these studies [17,
18] indicate that TCTP binds to the actin cytoskele-
ton and that, in addition to the negative feedback sig-
naling between TCTP and p53, there is also negative
feedback signaling between TCTP and actin expres-
sion in ovarian cancer cells. Interestingly, the most
recent studies have shown that there is also a cross-
talk between the TCTP, cyclin A, RhoA and actin
distribution [36, 45], which may be responsible for the
increased migratory activity of cancer cells. Arsic et
al. [37] showed that cyclin A2 expression is downreg-
ulated in metastatic colon adenocarcinoma in humans.
Our present study shows that also in ovarian can-
cer cells there is an extensive down-regulation of cy-
clin A expression, which may be responsible for their
high invasiveness. In addition, we found that the
OVCAR3 and SKOV3 ovarian cancer cell lines did
not express full length cyclin A, but only its truncated
isoform. The truncated isoforms of cyclins lacking
specific regulatory sequences that modulate their sta-
bility, subcellular localization or cdk-associated kinase
activity are expressed in various cancers [46, 47].
Moreover, studies on mouse embryos, fibroblasts,
stem and cancer cells have shown that in many in-
stances cyclin A is dispensable for the progression of
the cell cycle and when downregulated it is replaced
by cyclin E [48, 49]. Our data shows that the down
regulation of cyclin A in OVCAR3 and SKOV3 cells
correlated with the upregulation of RhoA. In con-
trast, Arsic et al. [37] showed that in human adeno-
carcinoma, cyclin A2 depletion correlated with
a downregulation of RhoA activity. This discrepancy
may indicate that the relationship between the cyclin
A and RhoA expression levels and activity is either
cell specific or much more complex than previously
believed.
In conclusion, our findings suggest the existence
of novel, and thus far unexplored, interactions be-
tween TCTP, p53, RhoA, cyclin A and the cytoskele-
ton. These interactions are of possible importance in
oncogenic transformation.
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